Pipeline

DISC O V ERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 DEVELOPMENT STAGE & ANTICIPATED MILESTONES COMMERCIAL RIGHTS PROGRAM THERAPEUTIC INDICATION Anti-Inflammatory Checkpoint Modulator T S R -042: Anti-PD-1 T S R -022: Anti - TIM-3 T S R -033: Anti-LAG-3 TSR-075: Anti-PD-1/LAG-3 Bispecific C C -90006: Anti-PD-1 Agonist Undisclosed Etokimab (ANB020):Anti-IL-33 ANB019: Anti - I L -36R Generalized Pustular Psoriasis Palmoplantar Pustulosis Inflammation Immuno-Oncology Immuno-Oncology Immuno-Oncology Immuno-Oncology Psoriasis Inflammation Phase 2a Data Presented at AAD and EAACI 2018 ATLAS: Phase 2bTop-Line Data H2 2019 Phase 2a Top-Line Data Announced March 2018 ECLIPSE: Phase 2 To Be InitiatedTop-Line Data H2 2019 GALLOP: Phase 2Top-Line Data Early 2019 Registration TrialOngoing TSR-042 Combination Trial Ongoing IND Filing H2 2019 IND-EnablingStudies Ongoing Ongoing Ongoing Ongoing Moderate-to-Severe Baseline Adult Peanut Allergy Top-Line Data Announced November 2017 POPLAR: Phase 2 To Be InitiatedTop-Line Data H2 2019 Presented at EAACI 2018 Phase 1 Data Moderate-to-Severe Adult Atopic Dermatitis Severe Adult Eosinophilic Asthma Adult Chronic Rhinosinusitis With Nasal Polyps